Results 81 to 90 of about 39,340 (291)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Cost effectiveness analysis for commonly used human cell and tissue products in the management of diabetic foot ulcers

Health Science Reports
Background and Aims This study considers the cost‐effectiveness of commonly used cellular, acellular, and matrix‑like products (CAMPs) of human origin also known as human cell and tissue products (HCT/Ps) in the management of diabetic foot ulcers ...
Leo M. Nherera, Jaideep Banerjee
doaj   +1 more source

Health Economic Evaluation of Patients With Colorectal Liver Metastases Randomized to ALPPS or TSH: Analysis From the LIGRO Trial

Annals of Surgery Open
Objective:. This is a preplanned, health economic evaluation from the LIGRO trial. One hundred patients with colorectal liver metastases (CRLM) and standardized future liver remnant
Kristina Hasselgren, MD, PhD, Martin Henriksson, PhD, Bård I. Røsok, MD, PhD, Peter N. Larsen, MD, PhD, Ernesto Sparrelid, MD, PhD, Gert Lindell, MD, PhD, Nicolai A. Schultz, MD, PhD, Bjorn A. Bjørnbeth, MD, PhD, Bengt Isaksson, MD, PhD, Magnus Rizell, MD, PhD, Anna Lindhoff Larsson, RN, Per Sandström, MD, PhD, Bergthor Björnsson, MD, PhD   +12 more
doaj   +1 more source

A test of the predictive validity of non-linear QALY models using time trade-off utilities [PDF]

This paper presents a test of the predictive validity of various classes of QALY models (i.e., linear, power and exponential models). We first estimated TTO utilities for 43 EQ-5D chronic health states and next these states were embedded in health ...
José Luis Pinto, Xabier Badía, José Mª Abellán, Ildefonso Méndez   +3 more
core  

Health losses (QALYs).

, 2021
R and the efficacy against transmission vary and are labelled on the side (R) and the top (efficacy). Community infections refers to QALYs lost from acute COVID infections that do not result in hospitalization.
Paul Tupper (11098871), Erin Kirwin (7547093), Christopher McCabe (206680), Nicola Mulberry (7376975), Caroline Colijn (164960)   +4 more
core   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Total QALYs and incremental QALYs (lifetime horizon, discounted).

Total QALYs and incremental QALYs (lifetime horizon, discounted).
Tim Andre Kanters (17720715), Adrian Stuart Wagg (17720718), Maiwenn Johanna Al (17720724), Katharina Abraham (17720712), Nicole Huige (15252725), Edward Hutt (17720721)   +5 more
core   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

The cost-effectiveness analysis of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair deficient advanced colorectal cancer

Scientific Reports
Research probing the clinical utility of immune checkpoint inhibitors (ICIs) supports the development of novel, efficacious approaches to treating colorectal cancer (CRC) patients without chemotherapy.
Pei Yang, Zhengda Pei, Yuan Zhou, Haiping Pei   +3 more
doaj   +1 more source

QALYs: Some Challenges

Value in Health, 2009
In the preceding article, Weinstein et al. [1] explain the QALYconcept, its methods, and their underlying assumptions. Anumber of interesting themes for discussion arise from thisfactual presentation. We restrict ourselves to addressing fourissues that we deem particularly challenging.As a general background for our selection of issues, we reit-erate a
Nord, Erik, Daniels, Norman, Kamlet, Mark   +2 more
openaire   +2 more sources